Overall, consistent findings across multiple studies underscore the potential of EZH2 as a therapeutic target and prognostic biomarker in HCC while emphasizing the need for further research to clarify its mechanistic pathways and interactions within the tumor microenvironment. This evidence concerns the gene EZH2 and neoplasm.